Mutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibility
暂无分享,去创建一个
C. Ricketts | W. Kaelin | P. Ratcliffe | C. Schofield | E. Maher | R. Chowdhury | G. Kirby | M. McDonough | B. Carter | F. Latif | D. Astuti | D. Gentle | S. Schlisio | R. Kenchappa
[1] P. Camacho. Clinical Endocrinology and Metabolism , 2011 .
[2] Haiguo Wu,et al. Targeted high throughput sequencing of a cancer-related exome subset by specific sequence capture with a fully automated microarray platform. , 2010, Genomics.
[3] Fiona Douglas,et al. Tumor risks and genotype–phenotype–proteotype analysis in 358 patients with germline mutations in SDHB and SDHD , 2010, Human mutation.
[4] C. Ricketts,et al. Identification of Candidate Tumour Suppressor Genes Frequently Methylated in Renal Cell Carcinoma , 2009, Oncogene.
[5] Gurpreet W. Tang,et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes , 2009, Nature.
[6] C. Domene,et al. Structural basis for binding of hypoxia-inducible factor to the oxygen-sensing prolyl hydroxylases. , 2009, Structure.
[7] J. Stamatoyannopoulos,et al. Power of deep, all-exon resequencing for discovery of human trait genes , 2009, Proceedings of the National Academy of Sciences.
[8] F. Galateau-Sallé,et al. PHD2 mutation and congenital erythrocytosis with paraganglioma. , 2008, The New England journal of medicine.
[9] S. Richard,et al. Familial Non-VHL Clear Cell (Conventional) Renal Cell Carcinoma: Clinical Features, Segregation Analysis, and Mutation Analysis of FLCN , 2008, Clinical Cancer Research.
[10] C. Ricketts,et al. Germline SDHB mutations and familial renal cell carcinoma. , 2008, Journal of the National Cancer Institute.
[11] M. Meyerson,et al. The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. , 2008, Genes & development.
[12] P. Carmeliet,et al. Abnormal Sympathoadrenal Development and Systemic Hypotension in PHD3−/− Mice , 2008, Molecular and Cellular Biology.
[13] H. Wajcman,et al. Disturbance in the HIF-1alpha pathway associated with erythrocytosis: further evidences brought by frameshift and nonsense mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene. , 2008, Blood cells, molecules & diseases.
[14] Eleanor A. L. Bagg,et al. Kinetic Rationale for Selectivity toward N- and C-terminal Oxygen-dependent Degradation Domain Substrates Mediated by a Loop Region of Hypoxia-Inducible Factor Prolyl Hydroxylases* , 2008, Journal of Biological Chemistry.
[15] W. Krek,et al. Multitasking by pVHL in tumour suppression. , 2007, Current opinion in cell biology.
[16] L. del Peso,et al. Identification of a region on hypoxia-inducible-factor prolyl 4-hydroxylases that determines their specificity for the oxygen degradation domains. , 2007, The Biochemical journal.
[17] Min Gyu Lee,et al. Drosophila UTX Is a Histone H3 Lys27 Demethylase That Colocalizes with the Elongating Form of RNA Polymerase II , 2007, Molecular and Cellular Biology.
[18] M. McMullin,et al. A novel erythrocytosis-associated PHD2 mutation suggests the location of a HIF binding groove. , 2007, Blood.
[19] M. Mannelli,et al. Genetic screening for pheochromocytoma: should SDHC gene analysis be included? , 2007, Journal of Medical Genetics.
[20] E. Maher,et al. Genotype–phenotype correlations in von Hippel‐Lindau disease , 2004, Human mutation.
[21] G. Stamp,et al. Expression of HIF-1α, HIF-2α (EPAS1), and Their Target Genes in Paraganglioma and Pheochromocytoma with VHL and SDH Mutations , 2006 .
[22] J. Zondlo,et al. Cellular oxygen sensing: Crystal structure of hypoxia-inducible factor prolyl hydroxylase (PHD2). , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[23] P. Barker,et al. Ligand-Dependent Cleavage of the P75 Neurotrophin Receptor Is Necessary for NRIF Nuclear Translocation and Apoptosis in Sympathetic Neurons , 2006, Neuron.
[24] C. Taylor,et al. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. , 2006, Cancer research.
[25] M. McMullin,et al. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[26] G. Stamp,et al. Expression of HIF-1alpha, HIF-2alpha (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations. , 2006, The Journal of clinical endocrinology and metabolism.
[27] C. Eng,et al. Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. , 2005, JAMA.
[28] W. Kaelin,et al. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. , 2005, Cancer cell.
[29] Patrick H. Maxwell,et al. Contrasting Properties of Hypoxia-Inducible Factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-Associated Renal Cell Carcinoma , 2005, Molecular and Cellular Biology.
[30] K. Schlingensiepen,et al. The role of Jun transcription factor expression and phosphorylation in neuronal differentiation, neuronal cell death, and plastic adaptationsin vivo , 1994, Cellular and molecular neurobiology.
[31] Eyal Gottlieb,et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. , 2005, Cancer cell.
[32] David G. Watson,et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. , 2005, Cancer cell.
[33] J. Schipper,et al. Germline Mutations in Non-syndromic Pheochromocytoma , 2004 .
[34] A. Harris,et al. Differential Function of the Prolyl Hydroxylases PHD1, PHD2, and PHD3 in the Regulation of Hypoxia-inducible Factor* , 2004, Journal of Biological Chemistry.
[35] H. Moch,et al. Molecular genetic analysis of FIH-1, FH, and SDHB candidate tumour suppressor genes in renal cell carcinoma , 2004, Journal of Clinical Pathology.
[36] L. Aaltonen,et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. , 2004, American journal of human genetics.
[37] W. Kaelin,et al. Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth , 2003, PLoS biology.
[38] J. Prchal,et al. Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia. , 2003, American journal of human genetics.
[39] P. Sutphin,et al. Role of Prolyl Hydroxylation in Oncogenically Stabilized Hypoxia-inducible Factor-1α* , 2002, The Journal of Biological Chemistry.
[40] R. Wisdom,et al. c-jun is essential for sympathetic neuronal death induced by NGF withdrawal but not by p75 activation , 2002, The Journal of cell biology.
[41] J. Schipper,et al. Germ-line mutations in nonsyndromic pheochromocytoma. , 2002, The New England journal of medicine.
[42] S. McKnight,et al. A Conserved Family of Prolyl-4-Hydroxylases That Modify HIF , 2001, Science.
[43] Michael I. Wilson,et al. C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation , 2001, Cell.
[44] P. Ratcliffe,et al. Independent function of two destruction domains in hypoxia‐inducible factor‐α chains activated by prolyl hydroxylation , 2001, The EMBO journal.
[45] E S Husebye,et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. , 2001, American journal of human genetics.
[46] S. White,et al. Dynamic, site-specific interaction of hypoxia-inducible factor-1alpha with the von Hippel-Lindau tumor suppressor protein. , 2001, Cancer research.
[47] P. Ratcliffe,et al. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. , 2001, Human molecular genetics.
[48] M. Ivan,et al. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. , 2001, Human molecular genetics.
[49] D. Evans,et al. Germline SDHD mutation in familial phaeochromocytoma , 2001, The Lancet.
[50] M. Ivan,et al. HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing , 2001, Science.
[51] Michael I. Wilson,et al. Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation , 2001, Science.
[52] C. Eng,et al. Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma. , 2000, Cancer research.
[53] B. Devlin,et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. , 2000, Science.
[54] C. Wykoff,et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.
[55] B. Ponder,et al. Genetic predisposition to phaeochromocytoma: analysis of candidate genes GDNF, RET and VHL. , 1997, Human molecular genetics.
[56] S. Chew,et al. Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas. , 1995, Journal of medical genetics.
[57] Michael E. Greenberg,et al. Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis , 1995, Science.
[58] B. Ponder,et al. Molecular genetic diagnosis of von Hippel-Lindau disease in familial phaeochromocytoma. , 1995, Journal of medical genetics.
[59] L. Rubin,et al. A c-jun dominant negative mutant protects sympathetic neurons against programmed cell death , 1995, Neuron.
[60] S. Estus,et al. Altered gene expression in neurons during programmed cell death: identification of c-jun as necessary for neuronal apoptosis , 1994, The Journal of cell biology.
[61] M. Ferguson-Smith,et al. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. , 1994, Human molecular genetics.
[62] J. Brooks,et al. Mutations of the VHL tumour suppressor gene in renal carcinoma , 1994, Nature Genetics.
[63] J. Gnarra,et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.
[64] M. Ferguson-Smith,et al. Clinical features and natural history of von Hippel-Lindau disease. , 1990, The Quarterly journal of medicine.
[65] B. Cowan,et al. A Family Is , 1981 .
[66] C. Perry. Clinical Features , 2004, Bristol medico-chirurgical journal.